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Abstract
IMPORTANCE The COVID-19 pandemic continues to affect millions of people globally, with
increasing reports of neurological manifestations but limited data on their incidence and associations
with outcome.
OBJECTIVE To determine the neurological phenotypes, incidence, and outcomes among adults
hospitalized with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS This cohort study included patients with clinically
diagnosed or laboratory-confirmed COVID-19 at 28 centers, representing 13 countries and 4
continents. The study was performed by the Global Consortium Study of Neurologic Dysfunction in
COVID-19 (GCS-NeuroCOVID) from March 1 to September 30, 2020, and the European Academy of
Neurology (EAN) Neuro-COVID Registry (ENERGY) from March to October 2020. Three cohorts
were included: (1) the GCS-NeuroCOVID all COVID-19 cohort (n = 3055), which included consecutive
hospitalized patients with COVID-19 with and without neurological manifestations; (2) the
GCS-NeuroCOVID COVID-19 neurological cohort (n = 475), which comprised consecutive patients
hospitalized with COVID-19 who had confirmed neurological manifestations; and (3) the ENERGY
cohort (n = 214), which included patients with COVID-19 who received formal neurological
consultation.
EXPOSURES Clinically diagnosed or laboratory-confirmed COVID-19.
MAIN OUTCOMES AND MEASURES Neurological phenotypes were classified as self-reported
symptoms or neurological signs and/or syndromes assessed by clinical evaluation. Composite
incidence was reported for groups with at least 1 neurological manifestation. The main outcome
measure was in-hospital mortality.
RESULTS Of the 3055 patients in the all COVID-19 cohort, 1742 (57%) were men, and the mean age
was 59.9 years (95% CI, 59.3-60.6 years). Of the 475 patients in the COVID-19 neurological cohort,
262 (55%) were men, and the mean age was 62.6 years (95% CI, 61.1-64.1 years). Of the 214 patients
in the ENERGY cohort, 133 (62%) were men, and the mean age was 67 years (95% CI, 52-78 years).
A total of 3083 of 3743 patients (82%) across cohorts had any neurological manifestation (self-
reported neurological symptoms and/or clinically captured neurological sign and/or syndrome). The
most common self-reported symptoms included headache (1385 of 3732 patients [37%]) and
anosmia or ageusia (977 of 3700 patients [26%]). The most prevalent neurological signs and/or
syndromes were acute encephalopathy (1845 of 3740 patients [49%]), coma (649 of 3737 patients
[17%]), and stroke (222 of 3737 patients [6%]), while meningitis and/or encephalitis were rare (19 of
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Abstract (continued)
3741 patients [0.5%]). Presence of clinically captured neurologic signs and/or syndromes was
associated with increased risk of in-hospital death (adjusted odds ratio [aOR], 5.99; 95% CI,
4.33-8.28) after adjusting for study site, age, sex, race, and ethnicity. Presence of preexisting
neurological disorders (aOR, 2.23; 95% CI, 1.80-2.75) was associated with increased risk of
developing neurological signs and/or syndromes with COVID-19.
CONCLUSIONS AND RELEVANCE In this multicohort study, neurological manifestations were
prevalent among patients hospitalized with COVID-19 and were associated with higher in-hospital
mortality. Preexisting neurological disorders were associated with increased risk of developing
neurological signs and/or syndromes in COVID-19.
JAMA Network Open. 2021;4(5):e2112131. doi:10.1001/jamanetworkopen.2021.12131
Introduction
The COVID-19 pandemic continues to affect millions of people globally, with increasing burdens of
morbidity and mortality. More reports describe concomitant COVID-19 neurological
manifestations,1-5 including symptoms such as headache, myalgia, anosmia, and ageusia as well as
neurological syndromes such as encephalopathy, stroke, and coma, among others.1,6-17 Reports
comprise case series8-10,18 and single and/or regional cohorts4,19-23 with varying data definitions,
limiting the ability to accurately estimate the incidence of COVID-19 neurological manifestations and
precluding data pooling and generalization across populations.24-26
To address this critical knowledge gap, 2 global consortia collaborated to establish worldwide
incidence, type, and outcomes of neurological manifestations among patients hospitalized with
COVID-19.24,25,27,28 The primary aims of this study were to (1) determine the incidence of COVID-19
neurological manifestations among global cohorts of hospitalized patients and (2) investigate the
association of neurological manifestations with in-hospital mortality. A secondary exploratory aim





The study population was derived from 2 large consortia: (1) the Global Consortium Study of
Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID), a large multicenter cohort study set up to
systematically establish the incidence, severity, and outcomes of neurological manifestations among
patients with COVID-19,27,28 and (2) the European Academy of Neurology (EAN) Neuro-COVID
Registry (ENERGY), a prospective registry established to evaluate the incidence of COVID-19
neurological manifestations and their outcomes at 6 and 12 months.24 The central coordinating
center of the GCS-NeuroCOVID established ethics approval for a multicenter study from the
University of Pittsburgh, confirmed local ethics approval with a waiver of informed consent because
of the observational nature of the study, and executed data use agreements with each participating
site. All centers that participated in the ENERGY Consortium received ethics committee approval,
and all patients in the ENERGY cohort provided written or verbal informed consent, depending on
requirements at each site. This study follows the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline.
The GCS-NeuroCOVID and ENERGY consortia have complementary global geographic reach
and established a formal partnership to harmonize common data elements in their respective case
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report forms (eTable 1 in the Supplement 1) and combine data in a general analysis of the global and
regional burden of COVID-19 neurological manifestations.25
Three separate cohorts were included in this study: (1) the GCS-NeuroCOVID all COVID-19
cohort (3055 patients at 6 sites), which included consecutive patients hospitalized with COVID-19
with and without neurological manifestations; (2) the GCS-NeuroCOVID COVID-19 neurological
cohort (475 patients at 9 sites), which included consecutive patients hospitalized with COVID-19 and
neurological manifestations; and (3) the ENERGY registry (214 patients at 13 sites), which included
patients with COVID-19 and neurological manifestations.
GCS-NeuroCOVID
The design, rationale, and data elements of GCS-NeuroCOVID study have been previously
published.27,28 The setting included secondary or tertiary centers caring for patients hospitalized
with COVID-19. Inclusion criteria were patients aged 18 or older admitted to an acute care hospital
with clinically diagnosed or laboratory-confirmed COVID-19. Exclusion criteria were patients with
severe preexisting neurological dysfunction, such as baseline coma or vegetative state, that
precluded determination of new neurological dysfunction. Race and ethnicity were recorded by local
investigators based on patient self-identification during routine clinical care, history, and clinical
examination. The GCS-NeuroCOVID Consortium included 2 separate cohorts. The all COVID-19
cohort included consecutive eligible patients over a 3-month study period regardless of neurological
manifestations. The COVID-19 neurological cohort included consecutive eligible patients who were
identified as having neurological manifestations over a 3-month study period. Both cohorts used the
same standardized case report form.
As part of the pragmatic design to promote feasibility, data elements were divided into core and
supplemental sections. Core elements were a robust minimal data set available regardless of care
settings and resource availability, posed minimal data collection burden on frontline clinicians, and
were mandatory from all sites. Supplemental data elements captured additional clinical features, and
reporting was encouraged but optional. By design, all data elements were available through history
and clinical observation and were not dependent on diagnostic testing availability, which may exhibit
center-specific variabilities due to service disruptions during a pandemic.28
ENERGY
The procedures of the European registry are detailed in a study protocol administered to
participating study sites.29,30 The setting included primary, secondary, and tertiary care centers
providing care to patients with COVID-19. Study inclusion criteria were as follows: aged 18 years or
older, clinically diagnosed COVID-19, case ascertainment through neurological consultation, and
patient informed consent. Neurologist members of the EAN or its affiliated national societies
registered consecutive patients fulfilling the inclusion criteria. Race/ethnicity were not recorded, as
most registered patients were White individuals; however, patients from populations with other
ethnic origins were confirmed by the local investigator. The ENERGY study included both
hospitalized and nonhospitalized patients; however, in harmonization with the GCS-NeuroCOVID
study, only hospitalized patient data were reported for this study. ENERGY data elements captured
general symptoms and signs and prominent comorbidities of COVID-19 as well as neurological
symptoms, signs, or diagnoses.
Neurological Manifestations
Neurological manifestations were differentiated into (1) self-reported symptoms (ie, headache,
anosmia and ageusia, history of syncope) and (2) neurological signs or diagnoses captured by clinical
evaluation (ie, acute encephalopathy, stroke, coma, seizure and/or status epilepticus, dysautonomia,
meningitis and/or encephalitis, myelopathy, plegia and/or paralysis, aphasia, movement
abnormalities, abnormal tone, abnormal brainstem reflexes, and sensory abnormalities). Overall
incidence of neurological manifestations was reported in 2 composite groups: the all neurological
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group included any patient with at least 1 self-reported neurological symptom and/or clinically
captured neurological sign or syndrome. To minimize ascertainment bias resulting from self-reported
symptoms, a separate signs and syndromes group was defined to include patients with at least 1
clinically captured neurological sign or syndrome.
Statistical Analysis
Descriptive statistics were provided for demographic and clinical characteristics of each cohort,
including incidence of composite and individual neurological manifestations. We reported the total
sample size available for each core and supplemental data element. No imputation was performed
for missing data. Due to the emergent nature of COVID-19 pandemic, there was no formal a priori
sample size and power calculations. Because the ENERGY and GCS-NeuroCOVID COVID-19
neurological cohorts did not include the general hospitalized COVID-19 population, subsequent
analyses of associations used only the GCS-NeuroCOVID all COVID-19 cohort to examine the
association of neurological signs and/or syndromes with outcome at hospital discharge.
We first evaluated the associations between demographic characteristics and neurological
manifestations with the risk of in-hospital death using logistic regression and reported odds ratios
(ORs) with 95% CIs from unadjusted and adjusted models. Models adjusted for known baseline
factors associated with COVID-19 mortality, ie, study center, age, age squared (higher order terms
were not statistically significant), sex, race, and ethnicity. Presence of multicollinearity was assessed
using the variance inflation factor. Because 1 of the 6 centers in the GCS-NeuroCOVID all COVID-19
cohort did not record body mass index (BMI; calculated as weight in kilograms divided by height in
meters squared), we only adjusted for BMI in secondary analyses. Because only 8 patients (0.3%)
were missing 1 or more of the adjustment covariates, we performed a complete case analysis.
We then explored the associations between demographic characteristics and preexisting
neurological conditions with the risk of developing clinically captured neurological signs and/or
syndromes using logistic regression. We report ORs and 95% CIs from unadjusted models and
models that adjusted for baseline characteristics (ie, age, age squared, sex, race, and ethnicity). The
null hypothesis was rejected with P < .05. All tests were 2-tailed. All analyses were performed using
JMP Pro version 14.0 (SAS Institute).
Results
Population Characteristics
Characteristics of all 3 cohorts are summarized in Table 1. The GCS-NeuroCOVID all COVID-19 cohort
included 3055 consecutive patients (1742 [57%] men; mean age, 59.9 years [95% CI, 59.3-60.6
years]) hospitalized with COVID-19 with and without neurological manifestations from 6 sites in the
US. The GCS-NeuroCOVID COVID-19 neurological cohort included 475 consecutive patients (262
[55%] men; mean age, 62.6 years [95% CI, 61.1-64.1 years]) hospitalized with COVID-19 with
neurological manifestations from 9 sites in the US and Egypt. The ENERGY registry included 214
patients (133 [62%] men; mean age, 67 years [95% CI, 52-78 years]) from 13 sites in Europe, Asia and
the Middle East, and Africa.
The cohorts consisted of predominantly White individuals (all COVID-19: 1474 [48%]; COVID-19
neurological: 207 [44%]); men; patients with overweight, ie, BMI greater than 25 (median
[interquartile range] BMI, all COVID-19: 29.7 [25.8-34.5]; COVID-19 neurological: 29.5 [24.6-35.7];
ENERGY: 26 [23-29]); and older patients. All 3 cohorts had a high incidence of underlying medical
conditions, such as diabetes, hypertension, and preexisting neurologic disorders. The proportion of
patients receiving mechanical ventilation ranged from 44 of 214 patients (21%) in the ENERGY cohort
to 186 of 475 patients (39%) in the COVID-19 neurological cohort. In-hospital mortality ranged from
30 of 209 patients (14%) in the ENERGY cohort to 113 of 460 patients (25%) in the COVID-19
neurological cohort.
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Incidence of Neurological Manifestations
We separately report the incidence of neurological manifestations for each cohort, as their different
entry requirements may affect observed calculated estimates. Only the GCS-NeuroCOVID all
COVID-19 cohort approximately reflected the general hospitalized COVID-19 population based on
entry criteria. All core data elements for neurological symptoms or clinically captured signs and/or
syndromes are reported with less than 5% missing data from the GCS-NeuroCOVID study cohorts
and less than 10% missing data from ENERGY registry (Table 2). Only a subset of study sites reported
supplemental data elements, which are available for 45 patients (21%) in the ENERGY cohort, 411
Table 1. Study Population Characteristics, Stratified by Cohorta
Characteristic








Sites, No. 13b 9 6
Geographic regions
United States
Northeast 0 34/475 (7) 2221/3055 (73)
Midwest 0 283/475 (60) 834/3055 (27)
South 0 99/475 (21) 0
Europe 167/214 (78) 0 0
Asia 30 (14) 0 0
Africa 17 (8) 59/475 (12) 0
Demographic characteristics
Sex
Men 133/214 (62) 262/475 (55) 1742/3055 (57)
Women 81/214 (38) 213/475 (45) 1313/3055 (43)
Age, mean (95% CI), y 67 (52-78) 62.6 (61.1-64.1) 59.9 (59.3-60.6)
Race
White NA 207/475 (44) 1474/3054 (48)
Black or African American NA 134/475 (28) 696/3054 (23)
Asian NA 16/475 (3) 133/3054 (4)
Otherc NA 98/475 (21) 572/3054 (19)
Unknown NA 20/475 (4) 179/3054 (6)
Hispanic ethnicity
Yes 1/45 (2) 52/473 (11) 697/3053 (23)
No 44/45 (98) 421/473 (89) 2356/3053 (77)
BMI, median (IQR) 26 (23-29) 29.5 (24.6-35.7) 29.7 (25.8-34.5)
Risk factors and past medical history
Preexisting neurological disorders 84/186 (45) 172/475 (36) 713/3055 (23)
Diabetesd 51/154 (33) 208/411 (51) 284/822 (35)
Coronary artery diseased 68/213 (32) 101/411 (25) 146/822 (18)
Hypertensiond 107/160 (67) 273/411 (66) 473/822 (58)
Cerebrovascular diseased 39/214 (18) 55/411 (13) 87/821 (11)
Immunosuppressedd 13/213 (6) 41/411 (10) 139/822 (17)
Lung diseased 31/214 (14) 102/410 (25) 169/822 (21)
Smokingd 20/213 (9) 61/411 (15) 183/818 (22)
Treatment intensity
ECMO 3/214 (1) 2/475 (<1) 40/3053 (1)
Dialysis 23/183 (13) 70/425 (16) 92/3054 (3)
Mechanical ventilation 44/214 (21) 186/475 (39) 867/3052 (28)
Hospital outcomes
Hospital LOS, median (IQR), de 23 (9-39) 10 (5-18) 8 (4-15)
Death 30/209 (14) 113/460 (25) 417/3049 (14)
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); EAN, European Academy of Neurology;
ECMO, extracorporeal membrane oxygenation;
ENERGY, European Academy of Neurology Neuro-
COVID Registry; GCS-NeuroCOVID, Global Consortium
Study of Neurological Manifestations of COVID-19;
IQR, interquartile range; LOS, length of stay; NA, not
available.
a The EAN ENERGY registry included patients with
COVID-19 and neurological features. The COVID-19
neurological cohort included patients with COVID-19
and neurological features. The all COVID-19 cohort
included patients with COVID-19, with and without
neurological features.
b Countries represented in the EAN ENERGY registry
included Austria, Hungary, Portugal, Italy, Turkey,
Switzerland, Tunisia, France, Egypt, Israel,
and Ukraine.
c Other races included American Indian, Pacific
Islander, unknown, and not recorded.
d Supplemental data elements capture additional
clinical features and baseline risk factors. Reporting
of supplemental data elements is optional, with
some but not all sites reporting these data.
e Data on hospital LOS were available for 29 patients
(14%) in the ENERGY cohort, 392 (83%) in the
COVID-19 neurological cohort, and 780 patients
(26%) in the all COVID-19 cohort.
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patients (87%) in the COVID-19 neurological cohort, and 822 patients (27%) in the all COVID-
19 cohort.
Across all 3 cohorts, headache was the most common self-reported symptom (Table 2), with
1165 of 3053 patients (38%) in the all COVID-19 cohort, 164 of 475 patients (35%) in the COVID-19
neurological cohort, and 56 of 204 patients (27%) in the ENERGY cohort, resulting in pooled
incidence of 37% (1385 of 3732 patients). Self-reported anosmia or ageusia was also common, with
840 of 3052 patients (28%) in the all COVID-19 cohort, 91 of 449 (20%) in the COVID-19 neurological
cohort, and 46 of 199 (23%) in the ENERGY cohort. Across cohorts, overall incidence of this
symptom was 26% (977 of 3700 patients). History of syncope was the least common symptom, with
an incidence of 152 of 3054 (5%) in the all COVID-19 cohort.
Acute encephalopathy was the most common clinically captured neurological sign and/or
syndrome in all cohorts (1845 of 3740 patients [49%]), with 1541 of 3053 patients (50%) in the all
COVID-19 cohort, 254 of 475 patients (53%) in the COVID-19 neurological cohort, and 50 of 212
patients (24%) in the ENERGY cohort. The next most common neurological signs and/or syndromes
were coma and stroke. The incidence of coma was 509 of 3049 patients (17%) in the all COVID-19
cohort, while coma was reported in 22 of 214 patients (10%) in the ENERGY cohort and 118 of 475
(25%) in the COVID-19 neurological cohort, resulting in a pooled estimate of 17% (649 of 3737
patients) across all groups. A total of 94 of 3054 patients (3%) had a stroke. In contrast, the 2
neurologically focused cohorts both reported a higher incidence of stroke, with 88 of 475 patients
(19%) in the COVID-19 neurological cohort and 40 of 208 patients (19%) in the ENERGY cohort. The
least common neurological signs or syndromes were meningitis and/or encephalitis (4 of 3053
patients [0.1%] in all COVID-19 cohort; pooled estimate, 0.5% [19 of 3741]) and myelopathy (6 of
3049 patients [0.2%] in all COVID-19 cohort), an observation consistent across all 3 cohorts (eFigure
in Supplement 1).
Table 2. Neurologic Manifestations in Study Population, Stratified by Cohorta
Manifestation









Any neurological manifestationb 169/214 (79) 475/475 (100) 2439/3054 (80)
Clinically captured signs or
syndromesc
151/169 (89) 385/475 (81) 1628/3055 (53)
Self-reported neurological symptoms
Headache 56/204 (27) 164/475 (35) 1165/3053 (38)
Anosmia or ageusia 46/199 (23) 91/449 (20) 840/3052 (28)
Syncope 4/212 (2) 58/475 (12) 152/3054 (5)
Clinically verified neurological signs
or syndromes
Acute encephalopathy 50/212 (24) 254/475 (53) 1541/3053 (50)
Stroke, all types 40/208 (19) 88/475 (19) 94/3054 (3)
Coma 22/214 (10) 118/475 (25) 509/3048 (17)
Seizure and/or status epilepticus 17/213 (8) 46/475 (10) 33/3053 (1)
Dysautonomia 16/197 (8) 20/475 (4) 37/3053 (1)
Meningitis and/or encephalitis 5/213 (2) 10/475 (2) 4/3053 (<1)
Myelopathy 6/213 (3) 13/474 (3) 6/3049 (<2)
Plegia and/or paralysisd 2/45 (4) 48/411 (12) 25/819 (3)
Aphasiad 0 47/411 (11) 15/308 (5)
New movement abnormalitiesd NA 19/411 (5) 24/814 (3)
Abnormal toned 2/45 (4) 51/411 (12) 14/304 (4)
Abnormal brainstem reflexesd 1/44 (2) 21/352 (6) 23/282 (8)
Sensory abnormalitiesc 1/45 (2) 51/411 (12) 15/812 (2)
Abbreviations: EAN, European Academy of Neurology;
ENERGY, European Academy of Neurology Neuro-
COVID Registry; GCS-NeuroCOVID, Global Consortium
Study of Neurological Manifestations of COVID-19; NA,
not available.
a The EAN ENERGY registry included patients with
COVID-19 and neurological features. The COVID-19
neurological cohort included patients with COVID-19
and neurological features. The all COVID-19 cohort
included patients with COVID-19, with and without
neurological features.
b Presence of any self-reported neurological
symptoms or clinically verified neurological signs or
syndromes.
c Presence of any clinically verified neurological sign or
syndrome.
d Supplemental data elements capture additional
clinical features and baseline risk factors. Reporting
of supplemental data elements is optional with some
but not all sites reporting these data.
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Across all cohorts, 3083 of 3743 patients (82%) across cohorts had any neurological
manifestation. In the all COVID-19 cohort, 2439 of 3054 patients (80%) had any neurological
manifestation, either self-reported and/or clinically captured (ie, the all neurological group).
Excluding self-reported symptoms, incidence of any clinically captured neurological sign or syndrome
(ie, the signs or syndromes group) was 53% (1628 of 3055 patients) in the all COVID-19 cohort and
between 81% and 89% in the other 2 neurologically focused cohorts (385 of 475 patients [81%] in
COVID-19 neurological; 151 of 169 [89%] in ENERGY).
In the all COVID-19 cohort, 1098 of 1312 women (84%) had any neurological manifestation, and
1341 of 1742 men (77%) had any neurological manifestation (Table 3). A total of 969 of 1742 men
(56%) and 659 of 1313 women (50%) had clinically captured neurological signs or syndromes;
incidence steadily increased across age groups, from 158 of 452 patients (35%) younger than 40
years to 307 of 398 patients (77%) older than 80 years. Self-reported symptoms such as headache
and anosmia were more common in women than in men (headache: 581 of 1312 [44%] vs 584 of 1741
[34%]; anosmia or ageusia: 411 of 1311 [31%] vs 429 of 1741 [25%]), and their incidence decreased
with age, from 223 of 452 (49%) in those younger than 40 years to 90 of 397 (23%) in those older
than 80 years. Anosmia or ageusia similarly decreased from 184 of 452 (41%) in those younger than
40 years to 266 of 1136 (23%) in those older than 80 years. Acute encephalopathy was present in
916 of 1741 men (53%) and 625 of 1312 women (48%), and its incidence increased steadily with age,
from 151 of 452 (33%) in those younger than 40 years to 293 of 397 (74%) in those older than
80 years.
Table 3. Incidence of Neurological Manifestations by Sex and Age in the All COVID-19 Cohort
Manifestation
No. of events/No. of individuals (%)
Sex Age group, y
Male (n = 1742) Female (n = 1313) <40 (n = 452) 40-60 (n = 1059) 61-80 (n = 1136) >80 (n = 398)
Overall groupings
Any neurological manifestationa 1341/1742 (77) 1098/1312 (84) 368/452 (81) 813/1059 (77) 909/1136 (80) 343/397 (86)
Clinically captured signs or syndromesb 969/1742 (56) 659/1313 (50) 158/452 (35) 473/1059 (45) 689/1136 (61) 307/398 (77)
Self-reported neurological symptoms
Headache 584/1741 (34) 581/1312 (44) 223/452 (49) 477/1058 (45) 371/1161 (33) 90/397 (23)
Anosmia or ageusia 429/1741 (25) 411/1311 (31) 184/452 (41) 299/1057 (28) 266/1136 (23) 90/397(23)
Syncope 96/1742 (6) 56/1312 (4) 11/452 (2) 47/1059 (4) 64/1136 (6) 30/397 (8)
Clinically verified neurological signs
or syndromes
Acute encephalopathy 916/1741 (53) 625/1312 (48) 151/452 (33) 439/1058 (41) 657/1136 (58) 293/397 (74)
Stroke, all types 53/1742 (3) 41/1312 (3) 4/452 (1) 31/1059 (3) 44/1136 (4) 15/397 (4)
Coma 331/1736 (19) 178/1312 (14) 51/452 (11) 172/1056 (16) 234/1133 (21) 52/397 (13)
Seizure and/or status epilepticus 19/1742 (1) 14/1311 (1) 4/452 (1) 12/1059 (1) 15/1136 (1) 2/396 (1)
Dysautonomia 24/1742 (1) 13/1311 (1) 7/452 (2) 10/1059 (1) 17/1135 (1) 3/397 (1)
Meningitis and/or encephalitis 3/1741 (<1) 1/1312 (<1) 0 2/1058 (<1) 1/1136 (<1) 1/397 (<1)
Myelopathy 6/1738 (<1) 0 1/452 (<1) 4/1056 (<1) 1/1134 (<1) 0
Plegia and/or paralysisc 16/462 (3) 9/357 (3) 2/104 (2) 10/294 (3) 11/317 (3) 2/101 (2)
Aphasiac 9/180 (5) 6/128 (5) 2/24 (8) 4/109 (4) 6/127 (5) 3/45 (7)
New movement abnormalitiesc 14/459 (3) 12/355 (3) 2/102 (2) 11/292 (4) 10/317 (3) 3/100 (3)
Abnormal tonec 5/179 (3) 10/125 (8) 1/23 (4) 5/108 (5) 8/125 (6) 1/45 (2)
Abnormal brainstem reflexesc 16/163 (10) 7/119 (6) 0 9/101 (9) 12/116 (10) 2/41 (5)
Sensory abnormalitiesc 12/461 (3) 3/351(1) 0 7/293 (2) 6/313 (2) 2/101 (2)
a Presence of any self-reported neurological symptoms or clinically verified neurological
signs or syndromes.
b Presence of any clinically verified neurological sign or syndrome.
c Supplemental data elements capture additional clinical features and baseline risk
factors. Reporting of supplemental data elements is optional with some but not all sites
reporting these data.
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Neurological Manifestations and In-Hospital Mortality
The presence of any neurological symptom or clinically captured sign or syndrome was associated
with a higher risk of in-hospital death (OR, 1.77; 95% CI, 1.32-2.39) (Table 4; eTable 1 in Supplement 1).
When limited to clinically captured neurologic signs or syndromes, the magnitude of the association
with death was higher (OR, 6.41; 95% CI, 4.82-8.50). After adjusting for baseline differences by study
site, age, sex, race, and ethnicity, the presence of any clinically captured neurologic sign or syndrome
remained associated with an increased risk of death (aOR, 5.99; 95% CI, 4.33-8.28).
Self-reported neurological symptoms (ie, headache, anosmia or ageusia, syncope) were
associated with a reduced risk of in-hospital death, while clinically captured neurologic signs or
syndromes were associated with an increased risk of death (Table 4). After adjusting for baseline
differences in study site, age, sex, race, and ethnicity, self-reported headache and syncope remained
Table 4. Characteristics Associated With In-Hospital Death in All COVID-19 Cohort
Covariate
No. of deaths/No. of individuals (%) Unadjusted Adjusteda
Present Absent OR (95%CI) P value aOR (95% CI) P value
Baseline characteristics
Age, per 10-y increment NA NA 1.71 (1.59-1.84) <.001 1.74 (1.60-1.88) <.001
Male sex 270/1741 (16) 147/1308 (11) 1.45 (1.17-1.80) <.001 1.66 (1.31-2.10) <.001
Raceb
White 246/1469 (17) 0 1 [Reference] NA 1 [Reference] NA
Asian 10/132 (8) 0 0.41 (0.21-0.79) .008 0.39 (0.20-0.77) .007
African American 78/696 (11) 0 0.63 (0.48-0.82) <.001 0.81 (0.61-1.09) .16
Otherc 58/572 (10) 0 0.56 (0.41-0.76) <.001 1.05 (0.67-1.64) .83
Unknown 25/179 (14) 0 0.81 (0.52-1.26) .34 1.02 (0.63-1.64) .94
Hispanic ethnicity 63/697 (9) 354/2351 (15) 0.56 (0.42-0.74) <.001 0.86 (0.56-1.31) .47
Preexisting neurological disorders 134/712 (19) 283/2337 (12) 1.68 (1.34-2.11) <.001 1.19 (0.93-1.52) .17
Overall neurological groupings,
No. of events/No. of individuals (%)
Any neurological manifestationd 362/2435 (15) 55/614 (9) 1.77 (1.32-2.39) <.001 2.48 (1.70-3.62) <.001
Clinically captured signs or syndromese 357/1624 (22) 60/1425 (4) 6.41 (4.82-8.50) <.001 5.99 (4.33-8.28) <.001
Self-reported neurological symptoms,
No. of events/No. of individuals (%)
Headache 65/1161 (6) 352/1887 (19) 0.26 (0.20-0.34) <.001 0.33 (0.24-0.44) <.001
Anosmia or aguesia 89/840 (11) 328/2207 (15) 0.68 (0.53-0.87) .002 0.81 (0.62-1.07) .14
Syncope 7/151 (5) 410/2898 (14) 0.29 (0.14-0.63) <.001 0.22 (0.10-0.48) <.001
Neurologic signs or syndromes,
No. of events/No. of individuals (%)
Acute encephalopathy 340/1540 (22) 77/1508 (5) 5.27 (4.06-6.82) <.001 5.51 (4.01-7.57) <.001
Stroke, all types 22/94 (23) 395/2955 (13) 1.98 (1.21-3.23) .001 1.60 (0.95-2.68) .08
Coma 154/509 (30) 262/2534 (10) 3.76 (2.99-4.73) <.001 7.70 (5.65-10.50) <.001
Seizure and/or status epilepticus 6/33 (18) 411/3016 (14) 1.41 (0.58-3.43) .45 1.54 (0.59-3.99) .37
Meningitis and/or encephalitis 2/4 (50) 415/3044 (14) 6.33 (0.89-45.09) .07 7.33 (0.80-67.42) .08
Myelopathy 1/6 (17) 415/3038 (14) 1.26 (0.15-10.85) .83 1.62 (0.17-15.09) .67
Plegia and/or paralysisf 7/25 (28) 100/690 (13) 2.68 (1.09-6.59) .046 1.50 (0.53-4.26) .44
Aphasiaf 6/15 (40) 57/289 (20) 2.71 (0.93-7.93) .07 2.93 (0.91-9.41) .07
Sensory abnormalitiesf 5/15 (33) 100/793 (13) 3.47 (1.16-10.3) .04 1.12 (0.33-3.84) .85
Abnormal brainstem reflexesf 18/23 (78) 39/255 (15) 19.94 (6.99-56.85) <.001 24.28 (7.06-83.5) <.001
Movement abnormalitiesf 4/26 (15) 101/784 (13) 1.23 (0.42-3.64) .71 1.09 (0.34-3.47) .89
Abnormal tonef 6/15 (40) 56/285 (20) 2.73 (0.93-7.98) .07 4.53 (1.40-14.60) .02
Abbreviations: aOR, adjusted odds ratio; NA, not applicable; OR, odds ratio.
a Adjusted models include covariates study center, age, age squared (except when
estimating the OR for age), sex, race, and ethnicity.
b The P value for the overall group association of race with in-hospital was P < .001 for
unadjusted models and P = .03 for adjusted models.
c Other races included American Indian, Pacific Islander, unknown, and not recorded.
d Presence of any self-reported neurological symptoms or clinically verified neurological
signs or syndromes.
e Presence of any clinically verified neurological sign or syndrome.
f Supplemental data elements capture additional clinical features and baseline risk
factors. Reporting of supplemental data elements is optional with some but not all sites
reporting these data.
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associated with a reduced risk of in-hospital death (headache: aOR, 0.33; 95% CI, 0.24-0.44;
syncope: aOR, 0.22; 95% CI, 0.10-0.48). In contrast, clinically diagnosed neurological signs and/or
syndromes, such as acute encephalopathy, coma, and abnormal brainstem reflexes, were associated
with higher risk for in-hospital death (acute encephalopathy: aOR, 5.51; 95% CI, 4.01-7.57; coma: aOR,
7.70; 95% CI, 5.65-10.5; abnormal brainstem reflexes: aOR, 24.4; 95% CI, 7.06-83.5).
Risk Factors for New Neurological Signs and Syndromes
Using data from the all COVID-19 cohort, we found that multiple baseline characteristics, including
age, sex, race, ethnicity, and preexisting neurological disorders, were associated with an increased
risk of developing clinically captured neurological sign or syndrome with COVID-19 (Table 5). In a
model that mutually adjusted for these characteristics, older age (aOR per 10-year increment, 1.41;
95% CI, 1.34-1.48), male sex (aOR, 1.53; 1.30-1.82), White race (eg, Asian race vs White race: aOR,
0.62; 95% CI, 0.41-0.94), and preexisting neurological disorders (aOR, 2.23; 95% CI, 1.80-2.75) were
associated with the risk of developing neurological signs or syndromes with COVID-19.
Discussion
To our knowledge, this is the first and largest study of neurological manifestations in patients
hospitalized with COVID-19 across different cohorts and geographic regions. Neurological
manifestations ranged from self-reported symptoms to more severe neurological signs or syndromes
captured by clinical evaluation. Overall, 80% of these patients exhibited at least 1 new neurological
symptom, sign, or syndrome, and 55% had at least 1 neurological sign or syndrome captured on
clinical evaluation. We observed that acute encephalopathy was the most common neurological sign
or syndrome with an incidence of 50% across the 3 separate cohorts, while meningitis and/or
encephalitis and myelopathy were the least common, with incidences of 0.1% and 0.2%,
respectively. Furthermore, the presence of neurological signs or syndromes with COVID-19
significantly increased the risk of dying during acute hospitalization after adjusting for variations by
study site and baseline characteristics. Taken together, these observations highlight the importance
of neurological manifestations in COVID-19 and their potential impact on disease outcome.
In addition to reporting global incidence of COVID-19 neurological manifestations, we reported
the incidence of specific common neurological symptoms, signs, and syndromes across 3 different
cohort types. This reporting was important, as it highlighted variations in rates based on region and
cohort composition. Aggregating all data and presenting only pooled data could have resulted in
inaccurate estimates and an overstatement of actual signs and syndromes. Thus, the presentation of
Table 5. Baseline Characteristics Associated With Presence of Clinically Verified Neurological Signs or Syndromes in the All COVID-19 Cohort
Covariate
Patients, No./total No. (%) Unadjusted Adjusteda
Present Absent OR (95%CI) P value aOR (95%CI) P value
Age, per 10-y increment NA NA 1.39 (1.33-1.45) <.001 1.41 (1.34-1.48) <.001
Male sex 1004/1742 (58) 682/1313 (52) 1.26 (1.09-1.45) .002 1.53 (1.30-1.82) <.001
Raceb
White 886/1474 (60) 0 1 [Reference] NA 1 [Reference] NA
African American 324/696 (47) 0 0.41 (0.21-0.79) <.001 0.80 (0.65-0.99) .04
Asian 69/133 (52) 0 0.72 (0.50-1.02) .03 0.62 (0.41-0.94) .02
Otherc 299/572 (52) 0 0.71 (0.59-0.87) <.001 0.68 (0.51-0.90) .008
Unknown 108/179 (60) 0 1.01 (0.74-1.39) .80 0.99 (0.69-1.41) .94
Hispanic ethnicity 340/697 (49) 1286/2356 (55) 0.79 (0.67-0.94) .007 0.81 (0.62-1.05) .11
Preexisting neurological disorder 511/713 (72) 1175/2342 (50) 2.51 (2.09-3.01) <.001 2.23 (1.80-2.75) <.001
Abbreviations: aOR, adjusted odds ratio; NA, not applicable; OR, odds ratio.
a Adjusted models include covariates study center, age, age squared (except when
estimating the OR for age), sex, race, and ethnicity.
b The P value for the overall group association of race with in-hospital was P < .001 for
unadjusted models and P = .008 for adjusted models.
c Other races included American Indian, Pacific Islander, unknown, and not recorded.
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the data as distinct cohorts allowed for precise reporting of parameters, which was needed to
definitively build the science around these conditions within the setting of COVID-19 infection and to
compare outcomes between patients with COVID-19 with and without neurological manifestations.
Existing data from prior cohorts report incidence of acute encephalopathy ranging from 8% to
84%.6,10,20,21,31-33 In our large multicenter all COVID-19 patient cohort, we observed a 50% incidence
of acute encephalopathy. Meanwhile, our 2 cohorts with neurological manifestation as entry criteria
observed incidences of encephalopathy between 24% and 53%, likely reflecting differences in case
ascertainment and severity of illness in the underlying populations. Acute encephalopathy carried a
5-fold higher risk of in-hospital death after adjusting for known risk factors, including age. This was
consistent with another multicenter study31 showing acute encephalopathy in COVID-19 was more
prevalent in older patients with medical comorbidities, with higher need for critical care and worse
30-day mortality.
The incidence of other common neurological syndromes, such as stroke and coma, varied
among cohorts in our study. Existing studies with variable designs, sampling methods, and case
definitions have reported wide ranges for stroke incidence, from 1% to 46%.4,21,34,35 Our all
COVID-19 cohort observed stroke incidence at 3% in the hospitalized COVID-19 population, while our
neurologically focused COVID-19 neurological cohort and ENERGY cohort reported a higher stroke
incidence (19%), suggesting that clinical neurological syndromes, such as stroke, may be
overrepresented in populations captured by neurological entry criteria. Coma among patients with
COVID-19 has been reported,36 but its incidence is not known. Our study found coma incidence
ranges from 10% to 25%. The higher incidence of acute encephalopathy and coma in
GCS-NeuroCOVID cohorts compared with the ENERGY registry likely reflected differences in
population characteristics, such as the proportion of patients receiving mechanical ventilation.
Measured incidence of self-reported neurological symptoms from our collective cohorts was
within the range from existing literature: between 13% and 60% for headache37 and between 25%
and 68% for anosmia or ageusia38,39 The observation that self-reported neurological symptoms,
such as headaches, were associated with lower risk of death requires consideration. A separate
retrospective study38 also found that headache was associated with lower mortality in 576 patients
hospitalized with COVID-19. The observed association between self-reported neurological symptoms
and lower mortality may reflect ascertainment bias, where such data may be insufficiently captured
in patients with higher disease severity, particularly in the hospitalized COVID-19 population.
Consistent with existing reports, advanced age, male sex, White race, and higher BMI were
associated with higher mortality.36,40,41 In addition, we found that presence of neurological signs or
syndromes with COVID-19 carried a 5-fold higher risk for in-hospital death after adjusting for
differences between study sites and baseline characteristics. It is important to note that we did not
record the time or duration of the neurological observation and its association to in-hospital
mortality. Particularly among those with advanced illness, this is an important consideration and
should be included in future research. Despite this limitation, our findings were consistent with the
growing evidence from smaller cohort studies20,22,42-45 and supported the conclusion that
neurological manifestations with COVID-19 are an important risk factor for mortality. As such, a
formal neurological consultation may be warranted when neurological signs or symptoms are
suspected among individuals who test positive for COVID-19.
Our exploratory analysis found that in addition to baseline characteristics and underlying
medical conditions, having a preexisting neurological disorder was independently associated with
increased risk of developing neurological signs or syndromes with COVID-19. In our pragmatic study
design, we did not categorize preexisting neurological disorders, nor did we classify potential
etiologies of COVID-19 neurological signs or syndromes, which may have included exacerbation of
existing neurological pathology, development of de novo neurological syndromes, or neurological
complication of systemic illness.36,46 Additionally, less common neurological manifestations were
recorded as supplemental data elements. Although the denominators in these initial estimates were
small, as not all sites recorded this information, our preliminary findings highlighted possible
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presence of these phenotypes among hospitalized cohorts. To our knowledge, this was the first
report to detail these syndromes, and it warrants additional investigation in future research on
neurological manifestations in COVID-19. As such, these important questions will be addressed in
future tiers of the GCS-NeuroCOVID consortium studies. Meanwhile, this observation provides a first
general direction for identifying patients with COVID-19 who may be at higher risk of developing
neurological signs or syndromes.
Limitations
This study has limitations, including factors inherent in global cohort study design and data collection
in the midst of a pandemic and the fact that this was not a formal population-based study. Both the
GCS-NeuroCOVID and ENERGY consortia used a pragmatic design to facilitate rapid study launch and
data collection by frontline clinicians, as traditional research resources were limited during pandemic
surges. Both prospective and retrospective data capture were permitted, and this may have led to
ascertainment bias. There were no a priori sample size and power calculations, and study sample size
was based on available data from registered sites. Use of a global, multicenter approach may have
resulted in heterogeneity of reporting due to clinical settings and interobserver variabilities. To limit
infection exposure risk related to data collection, interrater reliability was not performed; however,
all sites used standardized data definitions and assessment guides to minimize variability. Because of
the variations in care delivery and research resource availability across global sites, our data set
captures different cohort types. Some sites were able to provide a control cohort and denominator
for calculating incidence of neurological manifestations by submitting data on all patients with
COVID-19 patients, including those without neurological manifestations (ie, the GCS-NeuroCOVID all
COVID-19 cohort). Other sites reported data solely among patients with COVID-19 and neurological
manifestations (ie, GCS-NeuroCOVID COVID-19 neurological and ENERGY cohorts). While these
differences limit the possibility of merging data across cohorts, inclusion of these different cohorts
allowed for comprehensive reporting across different populations. Furthermore, our study only
reports outcomes at hospital discharge and did not report detailed causes of death. Follow-up
studies are underway to determine the associations of neurological manifestations with longer-term
outcomes and to capture delayed onset neurological manifestations beyond acute hospitalization.
Conclusions
This multicenter cohort study found that neurological manifestations in COVID-19 were highly
prevalent and associated with premature mortality. Using a global network with standardized
protocols and common data elements is critical to facilitate further studies to understand COVID-19
neurological manifestations, including disease progression, associations with long-term outcomes,
pathobiological mechanisms, and societal impact.
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